Penumbra (PEN) Wins Early THUNDERBOLT Use, Is The 12% Discount Below Fair Value Enough?
Penumbra (PEN) is back on investor radar after Novant Health reported successful clinical use of its newly cleared THUNDERBOLT computer assisted vacuum thrombectomy system for ischemic stroke treatment in North Carolina.
See our latest analysis for Penumbra.
Penumbra's recent THUNDERBOLT update comes as the stock trades at US$319.49, with a 1 year total shareholder return of 38.81%, while the 3 year total shareholder return of 5.32% and 5 year total shareholder return of 20.43% point to more moderate long term progress.
If this kind of medical technology story interests you, it can be useful to see what else is moving in related areas through 41 healthcare AI stocks.
After the THUNDERBOLT driven jump in attention and a 1 year return close to 39%, Penumbra at US$319.49 puts you at a fork in the road. Is this a fair entry now, or is patience the better call as valuation is weighed next?
Most Popular Narrative: 12.1% Undervalued
On the most followed view of Penumbra, a fair value of about $363 per share sits above the recent $319.49 close. This puts the focus firmly on growth assumptions and product adoption.
The soon-to-be-released STORM-PE randomized trial is poised to provide Level 1 evidence comparing Penumbra's thrombectomy technology to standard anticoagulation for pulmonary embolism. A positive outcome could expand guideline adoption, significantly accelerate procedure volumes, and drive substantial revenue growth by rapidly increasing penetration in a very underpenetrated, large market.
Want to see what revenue curve sits behind that fair value for Penumbra? The narrative leans on faster earnings, rising margins and a premium future multiple. Curious which exact levers do the heavy lifting here?
Result: Fair Value of $363.36 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Penumbra story still carries key risks, including potential setbacks in trials like STORM PE, as well as pressure from larger medtech competitors on pricing and margins.
Find out about the key risks to this Penumbra narrative.
Another View on Penumbra: Expensive on Earnings
The analyst narrative points to Penumbra trading about 12.1% below an estimated fair value of $363.36, yet the current P/E of 73.5x tells a tougher story. That is far above the US Medical Equipment industry at 26.7x, the peer average at 26.6x, and even the fair ratio of 27.7x. This gap suggests the market is already pricing in a lot of good news. The key question is whether you think that premium is justified or leaves little room for error.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Penumbra attracting mixed views on value and growth, it can help to move fast, review the underlying drivers yourself, and stress test the optimism by checking the 2 key rewards
Looking for more investment ideas beyond Penumbra?
If Penumbra has sharpened your focus on quality opportunities, do not stop here. Broadening your watchlist across styles and risk profiles can reveal ideas you might otherwise miss.
- Spot early stage opportunities that still meet strict quality filters by reviewing the 21 elite penny stocks with strong financials.
- Hunt for companies that combine quality fundamentals with prices that sit below many investors' radar through the 51 high quality undervalued stocks.
- Prioritise resilience and capital preservation by scanning the 84 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com